PIK3CA and head and neck squamous cell carcinoma: Currently, there are many clinical trials employing PI3K inhibitors as monotherapies against solid tumors, including a phase II clinical trial utilizing the p110γ inhibitor IPI-549 on locally advanced HNSCC [5,16].